SOURCE: Insight Pharma Reports

Insight Pharma Reports

June 15, 2015 10:00 ET

Insight Pharma Reports' The Human Microbiome Report

Biomedical Implications and Birth of a Market

NEEDHAM, MA--(Marketwired - June 15, 2015) - Insight Pharma Reports releases the report, The Human Microbiome: Biomedical Implications and Birth of a Market, which covers the evolution of microbiome research and its growth in the commercial market. Specific areas of study include microbial ecology, systems biology, diet, diagnostics, contributions in health and disease, and infectious disease.

This report focuses on biomedical aspects of human microbiome research, development, and commerce. It covers necessary background material, evolution of the field, progress in basic research, activities in the developing commercial market, deal activity, interviews with experts, and trends in microbiome research and commerce. Information for the report has been drawn from the scientific literature, discussions with knowledgeable individuals, and an online survey of people working in this area.

Organizations covered in this report include: Companies covered in this space include: 4D Pharma, ActoGenixAOBiome, AvidBiotics, CIPAC Limited, Enterome Bioscience, Human Longevity, Metabiomics, Microbiome Therapeutics, Miomics, OmniBiome Therapeutics, OptiBiotix, Osel Inc., OxThera, PathoGenetix, Rebiotix, Ritter Pharmaceuticals, Second Genome, Seres Health, uBiome, UCB, UC San Francisco, Vedanta, ViThera Pharmaceuticals, and Whole Biome.

Exclusive interview transcripts with the following experts include:

  • Peter DiLaura, President & CEO, Second Genome
  • Colleen Cutcliffe, CEO, Whole Biome
  • James Brown, PhD; Head, Computational Biology; Head, Microbiome Matrix Team; GlaxoSmithKline
  • Jack Gilbert, PhD, Environmental Microbiologist, Assoc. Prof., Department of Ecology & Evolution, Argonne National Laboratory
  • Glenn Tillotson, PhD, Senior Partner, TranScrip Partners, USA
  • Peter P. Lee, MD, Executive Chairman, Osel Inc.
  • Gregory Kuehn, VP Business Development and Marketing, Metabiomics
  • Stephen Elms, CEO, Miomics Bio-Therapeutics
  • Sydney M. Finegold, MD, Emeritus Professor of Medicine, and Emeritus Professor of Microbiology, Immunology, and Molecular Biology, UCLA School of Medicine; Staff Physician, Infectious Disease Section, VA Greater Los Angeles Healthcare System

For more information on this report, visit http://www.insightpharmareports.com/human-microbiome-report

About Insight Pharma Reports (http://www.InsightPharmaReports.com)
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute.

Contact Information